348 related articles for article (PubMed ID: 23018571)
1. Use of cardiac markers for monitoring of doxorubixin-induced cardiotoxicity in children with cancer.
Pongprot Y; Sittiwangkul R; Charoenkwan P; Silvilairat S
J Pediatr Hematol Oncol; 2012 Nov; 34(8):589-95. PubMed ID: 23018571
[TBL] [Abstract][Full Text] [Related]
2. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study.
Mavinkurve-Groothuis AM; Marcus KA; Pourier M; Loonen J; Feuth T; Hoogerbrugge PM; de Korte CL; Kapusta L
Eur Heart J Cardiovasc Imaging; 2013 Jun; 14(6):562-9. PubMed ID: 23109647
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children.
Sherief LM; Kamal AG; Khalek EA; Kamal NM; Soliman AA; Esh AM
Hematology; 2012 May; 17(3):151-6. PubMed ID: 22664114
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer.
Hayakawa H; Komada Y; Hirayama M; Hori H; Ito M; Sakurai M
Med Pediatr Oncol; 2001 Jul; 37(1):4-9. PubMed ID: 11466716
[TBL] [Abstract][Full Text] [Related]
5. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy.
Soker M; Kervancioglu M
Saudi Med J; 2005 Aug; 26(8):1197-202. PubMed ID: 16127512
[TBL] [Abstract][Full Text] [Related]
6. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction.
Nousiainen T; Vanninen E; Jantunen E; Puustinen J; Remes J; Rantala A; Vuolteenaho O; Hartikainen J
J Intern Med; 2002 Mar; 251(3):228-34. PubMed ID: 11886482
[TBL] [Abstract][Full Text] [Related]
7. Association of left ventricular diastolic dysfunction with elevated NT-pro-BNP in general intensive care unit patients with preserved ejection fraction: a complementary role of tissue Doppler imaging parameters and NT-pro-BNP levels for adverse outcome.
Ikonomidis I; Nikolaou M; Dimopoulou I; Paraskevaidis I; Lekakis J; Mavrou I; Tzanela M; Kopterides P; Tsangaris I; Armaganidis A; Kremastinos DT
Shock; 2010 Feb; 33(2):141-8. PubMed ID: 19487972
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of N-terminal pro-type-B natriuretic peptide and Doppler left ventricular diastolic variables in patients with chronic systolic heart failure stabilized by therapy.
Dini FL; Conti U; Fontanive P; Andreini D; Panicucci E; De Tommasi SM
Am J Cardiol; 2008 Aug; 102(4):463-8. PubMed ID: 18678307
[TBL] [Abstract][Full Text] [Related]
9. Are Biomarkers Predictive of Anthracycline-Induced Cardiac Dysfunction?
Malik A; Jeyaraj PA; Calton R; Uppal B; Negi P; Shankar A; Patil J; Mahajan MK
Asian Pac J Cancer Prev; 2016; 17(4):2301-5. PubMed ID: 27221934
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in beta-thalassemia major.
Kremastinos DT; Hamodraka E; Parissis J; Tsiapras D; Dima K; Maisel A
Am Heart J; 2010 Jan; 159(1):68-74. PubMed ID: 20102869
[TBL] [Abstract][Full Text] [Related]
11. Early predictors of myocardial disease in children and adolescents with type 1 diabetes mellitus.
Salem M; El Behery S; Adly A; Khalil D; El Hadidi E
Pediatr Diabetes; 2009 Dec; 10(8):513-21. PubMed ID: 19708908
[TBL] [Abstract][Full Text] [Related]
12. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
[TBL] [Abstract][Full Text] [Related]
13. Comparison of usefulness of N-terminal pro-brain natriuretic peptide as an independent predictor of cardiac function among admission cardiac serum biomarkers in patients with anterior wall versus nonanterior wall ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Haeck JD; Verouden NJ; Kuijt WJ; Koch KT; Van Straalen JP; Fischer J; Groenink M; Bilodeau L; Tijssen JG; Krucoff MW; De Winter RJ
Am J Cardiol; 2010 Apr; 105(8):1065-9. PubMed ID: 20381654
[TBL] [Abstract][Full Text] [Related]
14. Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy.
Blaes AH; Rehman A; Vock DM; Luo X; Menge M; Yee D; Missov E; Duprez D
Vasc Health Risk Manag; 2015; 11():591-4. PubMed ID: 26648730
[TBL] [Abstract][Full Text] [Related]
15. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults.
Dodos F; Halbsguth T; Erdmann E; Hoppe UC
Clin Res Cardiol; 2008 May; 97(5):318-26. PubMed ID: 18193371
[TBL] [Abstract][Full Text] [Related]
17. Relative role of NT-pro BNP and cardiac troponin T at 96 hours for estimation of infarct size and left ventricular function after acute myocardial infarction.
Steen H; Futterer S; Merten C; Jünger C; Katus HA; Giannitsis E
J Cardiovasc Magn Reson; 2007; 9(5):749-58. PubMed ID: 17891611
[TBL] [Abstract][Full Text] [Related]
18. Correlation between NT-pro BNP levels and early mitral annulus velocity (E') in patients with non-ST-segment elevation acute coronary syndrome.
Barbosa MM; Nunes Mdo C; Castro LR; Nominato LF; Alencar MC; Ribeiro AL
Echocardiography; 2008 Apr; 25(4):353-9. PubMed ID: 18177379
[TBL] [Abstract][Full Text] [Related]
19. Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction.
Kittiwarawut A; Vorasettakarnkij Y; Tanasanvimon S; Manasnayakorn S; Sriuranpong V
Asia Pac J Clin Oncol; 2013 Jun; 9(2):155-61. PubMed ID: 22897825
[TBL] [Abstract][Full Text] [Related]
20. Combined NT-pro-BNP and CW-Doppler ultrasound cardiac output monitoring (USCOM) in epirubicin and liposomal doxorubicin therapy.
Knobloch K; Tepe J; Rossner D; Lichtinghagen R; Luck HJ; Busch KH; Vogt PM
Int J Cardiol; 2008 Aug; 128(3):316-25. PubMed ID: 17707098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
